Silence TherapeuticsSLN +25.48%44 Quick Ratio is 9.83 as of Mar. 2026, which is 28% above its 10-year median of 7.70. GuruFocus rates SLN with a GF Score™ of 44/100 and a GF Value™ of $0.21 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 1,417 Biotechnology companies, Silence Therapeutics ranks better than 77.91% on this metric.
Silence Therapeutics has a quick ratio of 9.83. It generally indicates good short-term financial strength.
The historical rank and industry rank for Silence Therapeutics's Quick Ratio or its related term are showing as below:
SLN'
s Quick Ratio Range Over the Past 10 Years
Min: 2.99 Med: 7.7 Max: 33.02
Current: 9.83
During the past 13 years, Silence Therapeutics's highest Quick Ratio was 33.02. The lowest was 2.99. And the median was 7.70.
SLN's Quick Ratio is ranked better than 77.91% of 1417
companies
in the Biotechnology industry
Industry Median: 3.6
vs SLN: 9.83
Silence Therapeutics (NAS:SLN) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
Silence Therapeutics Quick Ratio Related Terms
Silence Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for Silence Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Silence Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Silence Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Silence Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where Silence Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
Silence Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Silence Therapeutics (SLN) has a Quick Ratio of 9.83 as of Mar. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Silence Therapeutics and its competitors. This is 28% above median its historical median of 7.70. Over the past decade, Silence Therapeutics' Quick Ratio has ranged from 2.99 to 33.02. According to the industry distribution chart, Silence Therapeutics ranks #313 out of 1417 companies in the Biotechnology industry, placing it in the top 22.1%.
Is Silence Therapeutics' Quick Ratio too high?
Silence Therapeutics' current Quick Ratio of 9.83 is 28% above median its 10-year median of 7.70. Over the past 10 years, this metric has ranged from a low of 2.99 to a high of 33.02. The Biotechnology industry median Quick Ratio is 3.60. Silence Therapeutics' value of 9.83 is 173.1% above this industry median. Based on the distribution chart, Silence Therapeutics ranks #313 out of 1417 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Silence Therapeutics has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Silence Therapeutics' Quick Ratio compare to CRBP and TTRX?
According to the Biotechnology industry distribution chart, Silence Therapeutics ranks #313 out of 1417 companies for Quick Ratio. This places Silence Therapeutics in the top 22% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.60. Silence Therapeutics' value of 9.83 is 173.1% above this benchmark. Historically, Silence Therapeutics' own Quick Ratio has ranged from 2.99 to 33.02 over the past decade. While the company's 10-year median is 7.70 vs. the industry median of 3.60, Silence Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.60, based on 1,417 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Silence Therapeutics's current Quick Ratio of 9.83 is 173.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on Silence Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Silence Therapeutics's current Quick Ratio is 9.83, which is 28% above median its own 10-year median of 7.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Silence Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Silence Therapeutics (SLN) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.21, compared to a current price of $9.16 — trading 4261.9% above its estimated fair value. The current Quick Ratio is 9.83, which is 28% above median its 10-year median of 7.70 and 173.1% above the Biotechnology industry median of 3.60. Silence Therapeutics' overall GF Score™ is 44/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For Silence Therapeutics (SLN), the current Quick Ratio is 9.83 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Silence Therapeutics (SLN) Overvalued in 2026?
Based on GuruFocus' analysis, Silence Therapeutics stock appears to be overvalued.
The current stock price of $9.16 is trading 4261.9% above its estimated GF Value™ of $0.21.
GuruFocus considers Silence Therapeutics to be Significantly Overvalued.
Key valuation signals for SLN:
Quick Ratio: 9.83 (28% above median its 10-year median of 7.70)
GF Value™: $0.21 vs. price of $9.16 (4261.9% above fair value)
Industry Position: 173.1% above the Biotechnology median (#313 of 1417)
No single metric tells the full story. See the SLN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid or siRNA. Using its mRNAi GOLD platform, the company has generated siRNA product candidates both for its internal development pipeline as well as for out-licensed programs with third-party collaborators. Its wholly owned pipeline is focused on three therapeutic areas: cardiovascular disease, hematology, and rare diseases. The different product candidates in its pipeline are Divesiran (SLN124), a siRNA product candidate that has the potential to treat several hematological disorders; Zerlasiran (SLN360), being developed as a potential treatment to reduce cardiovascular issues; SLN-312; SLN-548; and multiple other programs.
44GF Score
Get the complete analysis for SLN
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SLN has been successfully added to your 
